Duration of Dual Antiplatelet Therapy for Patients at High Bleeding Risk Undergoing PCI.

MLA

Valgimigli, Marco, et al. “Duration of Dual Antiplatelet Therapy for Patients at High Bleeding Risk Undergoing PCI.” Journal of the American College of Cardiology, vol. 78, no. 21, Nov. 2021, pp. 2060–72. EBSCOhost, https://doi.org/10.1016/j.jacc.2021.08.074.

APA

Valgimigli, M., Cao, D., Angiolillo, D. J., Bangalore, S., Bhatt, D. L., Ge, J., Hermiller, J., Makkar, R. R., Neumann, F.-J., Saito, S., Picon, H., Toelg, R., Maksoud, A., Chehab, B. M., Choi, J. W., Campo, G., De la Torre Hernandez, J. M., Kunadian, V., Sardella, G., … Mehran, R. (2021). Duration of Dual Antiplatelet Therapy for Patients at High Bleeding Risk Undergoing PCI. Journal of the American College of Cardiology, 78(21), 2060–2072. https://doi.org/10.1016/j.jacc.2021.08.074

Chicago

Valgimigli, Marco, Davide Cao, Dominick J Angiolillo, Sripal Bangalore, Deepak L Bhatt, Junbo Ge, James Hermiller, et al. 2021. “Duration of Dual Antiplatelet Therapy for Patients at High Bleeding Risk Undergoing PCI.” Journal of the American College of Cardiology 78 (21): 2060–72. doi:10.1016/j.jacc.2021.08.074.